Clinical Trial Update: A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of GEN1044 (DuoBody-CD3x5T4) in malignant solid tumors has been terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Esophageal Cancer
• Non-small Cell Lung Cancer
• Or Metastatic Solid Tumor
• Prostate Cancer
• Squamous Cell Carcinoma of Head and Neck
• Triple-negative Breast Cancer
• Uterine Cancer

Drugs mentioned

• GEN1044 (DuoBody-CD3x5T4)

Snippet

Sponsor: Genmab | Conditions: Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-02-01